VIRGINIA RETIREMENT SYSTEMS ET Al Takes Position in Twist Bioscience Corporation $TWST

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Twist Bioscience Corporation (NASDAQ:TWST) in the 2nd quarter, Holdings Channel reports. The fund acquired 15,938 shares of the company’s stock, valued at approximately $1,640,000.

Several other large investors also recently bought and sold shares of TWST. GAMMA Investing LLC increased its stake in Twist Bioscience by 24.4% during the 2nd quarter. GAMMA Investing LLC now owns 943 shares of the company’s stock valued at $97,000 after purchasing an additional 185 shares in the last quarter. Stifel Financial Corp lifted its stake in shares of Twist Bioscience by 3.6% during the fourth quarter. Stifel Financial Corp now owns 7,769 shares of the company’s stock worth $246,000 after buying an additional 271 shares during the period. California State Teachers Retirement System lifted its stake in shares of Twist Bioscience by 0.8% during the second quarter. California State Teachers Retirement System now owns 54,187 shares of the company’s stock worth $1,994,000 after buying an additional 442 shares during the period. PNC Financial Services Group Inc. grew its holdings in shares of Twist Bioscience by 89.7% during the first quarter. PNC Financial Services Group Inc. now owns 958 shares of the company’s stock valued at $46,000 after buying an additional 453 shares during the last quarter. Finally, Allworth Financial LP purchased a new stake in shares of Twist Bioscience during the second quarter valued at $62,000.

Twist Bioscience Trading Up 0.3%

NASDAQ TWST opened at $127.22 on Friday. The company has a market capitalization of $7.98 billion, a PE ratio of -57.31 and a beta of 2.22. The company has a fifty day moving average of $113.51 and a 200 day moving average of $79.33. Twist Bioscience Corporation has a 1 year low of $23.30 and a 1 year high of $155.44. The company has a debt-to-equity ratio of 0.03, a current ratio of 2.67 and a quick ratio of 2.38.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Monday, August 3rd. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.51) by ($0.05). The business had revenue of $118.38 million during the quarter, compared to analysts’ expectations of $114.55 million. Twist Bioscience had a negative net margin of 31.66% and a negative return on equity of 28.64%. Twist Bioscience’s revenue for the quarter was up 23.2% compared to the same quarter last year. During the same period in the previous year, the company posted $0.33 earnings per share. Research analysts forecast that Twist Bioscience Corporation will post -2.12 earnings per share for the current year.

Insider Activity

In related news, CFO Adam Laponis sold 2,399 shares of the firm’s stock in a transaction on Thursday, July 9th. The shares were sold at an average price of $94.33, for a total transaction of $226,297.67. Following the sale, the chief financial officer owned 110,276 shares in the company, valued at approximately $10,402,335.08. This trade represents a 2.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, SVP Paula Green sold 291 shares of Twist Bioscience stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $87.32, for a total transaction of $25,410.12. Following the completion of the transaction, the senior vice president directly owned 120,414 shares of the company’s stock, valued at $10,514,550.48. The trade was a 0.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last three months, insiders sold 193,109 shares of company stock valued at $24,049,024. 3.08% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the company. BWS Financial initiated coverage on Twist Bioscience in a research report on Wednesday. They issued a “sell” rating and a $45.00 target price on the stock. Leerink Partners set a $110.00 price target on Twist Bioscience in a research note on Thursday, July 16th. UBS Group began coverage on Twist Bioscience in a report on Wednesday. They issued a “neutral” rating and a $144.00 price objective on the stock. Robert W. Baird raised their price objective on Twist Bioscience from $113.00 to $115.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 4th. Finally, Guggenheim restated a “buy” rating on shares of Twist Bioscience in a research note on Monday, August 24th. Eight analysts have rated the stock with a Buy rating, two have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $98.45.

Twist Bioscience Company Profile

Twist Bioscience Corporation is a biotechnology company that develops and manufactures synthetic DNA using a proprietary silicon-based platform. The company serves researchers and organizations in biotechnology, pharmaceutical development, agriculture, industrial chemicals and academic research.

Its products include synthetic genes, gene fragments, oligonucleotides and DNA libraries used in research, drug discovery, diagnostics development and other applications. Twist also provides next-generation sequencing tools and products, including target-enrichment and sample-preparation solutions, as well as synthetic biology services that support the design and testing of biological systems.

Twist was founded in 2013 and is headquartered in South San Francisco, California.